News | January 9, 2014

EKF Diagnostics' Quo-Lab HbA1c Analyzer Secures IFCC Certification

EKF Diagnostics.jpg

Point-of-care analyzer meets all standards set by independent certifying bodies

EKF Diagnostics, a global diagnostics company, is pleased to announce that its Quo-Lab HbA1c point-of-care analyzer has successfully achieved International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) certification. 

The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed reference measurement procedure for HbA1c, accepted worldwide as the analytical control for traceability of HbA1c measurement.

To participate in the program manufacturers are required to register and report the results of twenty four samples (two per month) from across the measurement range. The samples are supplied by an IFCC Reference Laboratory.

“The awarding of this certification allows us to report results traceable to the IFCC reference method for quantitative determination of HbA1c,” said Gavin Jones, Diabetes Product Manager EKF Diagnostics.  “Together with the existing NGSP certification we achieved from 2012, the IFCC award demonstrates conclusively that Quo-Lab meets all of the demanding standards set by independent certifying bodies.” 

Glycated hemoglobin (HbA1c) testing is globally recognized as the gold standard in monitoring of diabetic patients, enabling more complete control of their disease management. The Quo-Lab analyzer offers laboratory accurate results from just 4 µL of blood with a user friendly interface, simplifying the process even further.

For more information, visit www.ekfdiagnostics.com.

SOURCE: EKF Diagnostics

Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers